Protein matrix vaccines and methods of making and administering such vaccines
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
1. A method of making a protein matrix vaccine composition, said method comprising (i) mixing an antigen of interest with a carrier protein and (ii) adding a linker that covalently cross-links the carrier protein to form a cross-linked carrier protein matrix, wherein no more than 50% of said antigen of interest is covalently cross-linked to said carrier protein.
2. The method of claim 1 , wherein said antigen of interest is entrapped with said cross-linked carrier protein.
3. The method of claim 1 , wherein said carrier protein is a multimer.
4. The method of claim 3 , wherein said multimer is a homomultimer.
5. The method of claim 1 , wherein said covalent cross-linking of carrier protein comprises a peptide bond between a primary amino group of a lysine side chain and a carboxy group of an aspartate or glutamate side chain.
6. The method of claim 1 , wherein said linker is selected from the group consisting of glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide, or bis-biazotized benzidine.
7. The method of claim 1 , wherein said linker is a bifunctional cross-linker.
8. The method of claim 7 , wherein said bifunctional cross-linker is glutaraldehyde, bis[sulfosuccinimidyl]suberate, or dimethyl adipimidate.
9. The method of claim 1 , wherein said carrier protein is diphtheria toxin, diphtheria toxoid, tetanus toxin, tetanus toxoid, Pseudomonas aeruginosa exotoxin A, cholera toxin B subunit, tetanus toxin fragment C, bacterial flagellin, pneumolysin, an outer membrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein, Escherichia coli heat labile enterotoxin, shiga-like toxin, human LTB protein, pneumolysin, listeriolysin O (or related proteins), a protein extract from whole bacterial cells, the dominant negative mutant (DNI) of the protective antigen of Bacillus anthracis , or Escherichia coli beta-galactosidase.
10. The method of claim 1 , wherein said antigen of interest comprises one or more antigens of interest.
11. The method of claim 10 , wherein said antigen of interest is a polysaccharide, a polyalcohol, or a poly amino acid.
12. The method of claim 10 , wherein said polysaccharide is a Streptococcus pneumoniae polysaccharide, Francisella tularensis polysaccharide, Bacillus anthracis polysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhi polysaccharide, Salmonella species polysaccharide, Shigella polysaccharide, or Neisseria meningitidis polysaccharide.
13. The method of claim 12 , wherein said Streptococcus pneumoniae polysaccharide is capsular type 1, 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 18A, 18B, 18C, 18F, 19A, 19B, 19C, 19F, 20, 21, 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31, 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B, 35F, 36, 37, 38, 39, 40, 41A, 41F, 42, 43, 44, 45, 46, 47A, 47F, or 48.
14. A method of making a vaccine composition comprising (i) mixing an antigen of interest with a carrier protein and (ii) initiating a cross-linking reaction with a cross-linking agent that crosslinks functional groups on said carrier protein, wherein no more than 50% of said antigen of interest is covalently cross-linked to said carrier protein.
15. The method of claim 14 , wherein said antigen of interest is entrapped with said cross-linked carrier protein.
16. The method of claim 14 , wherein said cross-linking agent is a bifunctional cross-linker.
17. The method of claim 16 , wherein said bifunctional cross-linker is glutaraldehyde, bis[sulfosuccinimidyl]suberate, or dimethyl adipimidate.